Half-year report · HY
2934.TEDINET S100XFQN
Period2025-06-01 → 2025-11-30
Filed2026-01-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥10.7bn | 2025-06-01 → 2025-11-30 | Cons. | Net sales |
| Revenue | ¥21.5bn | 2024-06-01 → 2025-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥10.8bn | 2024-06-01 → 2024-11-30 | Cons. | Net sales |
| Operating income | −¥143m | 2025-06-01 → 2025-11-30 | Cons. | Operating income |
| Operating income | ¥27m | 2024-06-01 → 2024-11-30 | Cons. | Operating income |
| Ordinary income | −¥132m | 2025-06-01 → 2025-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥232m | 2024-06-01 → 2025-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7m | 2024-06-01 → 2024-11-30 | Cons. | Ordinary income |
| Profit before tax | −¥176m | 2025-06-01 → 2025-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥13m | 2024-06-01 → 2024-11-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥191m | 2025-06-01 → 2025-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥88m | 2024-06-01 → 2025-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥21m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥187m | 2025-06-01 → 2025-11-30 | Cons. | Profit loss |
| Net income | −¥5m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss |
| Total assets | ¥9.9bn | at 2025-11-30 | Cons. | Assets |
| Total assets | ¥9.2bn | at 2025-05-31 | Cons. | Assets |
| Total assets | ¥9.7bn | at 2024-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.8bn | at 2025-11-30 | Cons. | Liabilities |
| Total liabilities | ¥7.2bn | at 2025-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥2.0bn | at 2025-11-30 | Cons. | Net assets |
| Net assets / equity | ¥2.0bn | at 2025-05-31 | Cons. | Net assets |
| Net assets / equity | ¥1.9bn | at 2024-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.1bn | at 2025-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.2bn | at 2025-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.0bn | at 2025-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.1bn | at 2025-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.8bn | at 2024-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.8bn | at 2024-05-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥103m | 2025-06-01 → 2025-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥509m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥13m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥924m | 2025-06-01 → 2025-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥471m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥220m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥722m | 2025-06-01 → 2025-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥623m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥139m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-36.36 | 2025-06-01 → 2025-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥17.42 | 2024-06-01 → 2025-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-4.32 | 2024-06-01 → 2024-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥17.21 | 2024-06-01 → 2025-05-31 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 14.2% | at 2025-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 15.3% | at 2025-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 11.5% | at 2024-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-06-01 → 2025-11-30 | −¥37m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-06-01 → 2025-11-30 | −¥37m |
| Reconciling Itemsreconciling | segment profit | 2025-06-01 → 2025-11-30 | −¥212m |
| Healthcare Marketing Businessreportable segment | revenue | 2025-06-01 → 2025-11-30 | ¥5.3bn |
| Healthcare Marketing Businessreportable segment | revenue external | 2025-06-01 → 2025-11-30 | ¥5.3bn |
| Healthcare Marketing Businessreportable segment | revenue intersegment | 2025-06-01 → 2025-11-30 | ¥20m |
| Healthcare Marketing Businessreportable segment | segment profit | 2025-06-01 → 2025-11-30 | ¥83m |
| Healthcare Sales Businessreportable segment | revenue | 2025-06-01 → 2025-11-30 | ¥2.8bn |
| Healthcare Sales Businessreportable segment | revenue external | 2025-06-01 → 2025-11-30 | ¥2.8bn |
| Healthcare Sales Businessreportable segment | revenue intersegment | 2025-06-01 → 2025-11-30 | ¥14m |
| Healthcare Sales Businessreportable segment | segment profit | 2025-06-01 → 2025-11-30 | −¥122m |
| Medical Care Sales Businessreportable segment | revenue | 2025-06-01 → 2025-11-30 | ¥2.6bn |
| Medical Care Sales Businessreportable segment | revenue external | 2025-06-01 → 2025-11-30 | ¥2.6bn |
| Medical Care Sales Businessreportable segment | revenue intersegment | 2025-06-01 → 2025-11-30 | ¥3m |
| Medical Care Sales Businessreportable segment | segment profit | 2025-06-01 → 2025-11-30 | ¥108m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-06-01 → 2025-11-30 | ¥10.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-06-01 → 2025-11-30 | ¥10.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-06-01 → 2025-11-30 | ¥37m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-06-01 → 2025-11-30 | ¥69m |
| Reconciling Itemsreconciling | revenue | 2024-06-01 → 2024-11-30 | −¥109m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-06-01 → 2024-11-30 | −¥109m |
| Reconciling Itemsreconciling | segment profit | 2024-06-01 → 2024-11-30 | −¥180m |
| Healthcare Marketing Businessreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥4.7bn |
| Healthcare Marketing Businessreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥4.6bn |
| Healthcare Marketing Businessreportable segment | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥96m |
| Healthcare Marketing Businessreportable segment | segment profit | 2024-06-01 → 2024-11-30 | −¥24m |
| Healthcare Sales Businessreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥3.2bn |
| Healthcare Sales Businessreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥3.2bn |
| Healthcare Sales Businessreportable segment | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥11m |
| Healthcare Sales Businessreportable segment | segment profit | 2024-06-01 → 2024-11-30 | −¥4m |
| Medical Care Sales Businessreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥3.1bn |
| Medical Care Sales Businessreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥3.1bn |
| Medical Care Sales Businessreportable segment | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥2m |
| Medical Care Sales Businessreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥236m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-06-01 → 2024-11-30 | ¥11.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-06-01 → 2024-11-30 | ¥10.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥109m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-06-01 → 2024-11-30 | ¥207m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 547
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)UHY東京監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)森 崎 恆 平 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)井 口 寛 之 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1InterimDuration | 10843838000 | JPY |
| Net sales (5-year summary) | InterimDuration | 10675438000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 21504496000 | JPY |
| Ordinary income loss (5-year summary) | Prior1InterimDuration | 7163000 | JPY |
| Ordinary income loss (5-year summary) | InterimDuration | -131763000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 231541000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1InterimDuration | -21455000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | InterimDuration | -191401000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 87570000 | JPY |
| Comprehensive income (5-year summary) | Prior1InterimDuration | -8629000 | JPY |
| Comprehensive income (5-year summary) | InterimDuration | -200443000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 127169000 | JPY |
| Net assets (5-year summary) | Prior1InterimInstant | 1873772000 | JPY |
| Net assets (5-year summary) | InterimInstant | 2015454000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 2014275000 | JPY |
| Total assets (5-year summary) | Prior1InterimInstant | 9736380000 | JPY |
| Total assets (5-year summary) | InterimInstant | 9856971000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 9172780000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1InterimDuration | -4.32 | |
| Basic earnings loss per share (5-year summary) | InterimDuration | -36.36 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 17.42 | |
| Diluted earnings per share (5-year summary) | Prior1InterimDuration | － | |
| Diluted earnings per share (5-year summary) | InterimDuration | － | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | 17.21 | |
| Equity to asset ratio (5-year summary) | Prior1InterimInstant | 0.115 | |
| Equity to asset ratio (5-year summary) | InterimInstant | 0.142 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.153 | |
| Net cash provided by used in operating activities (5-year summary) | Prior1InterimDuration | -12768000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | InterimDuration | 103459000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | 509015000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1InterimDuration | 219691000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | InterimDuration | -923932000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | 470793000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1InterimDuration | -139171000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | InterimDuration | 722326000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | -623129000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1InterimInstant | 1820717000 | JPY |
| Cash and cash equivalents (5-year summary) | InterimInstant | 2012270000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant | 2109645000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 5333465 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 5333465 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 5333465 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 5333465 | |
| Number of shares held | InterimInstant_No1MajorShareholdersMember | 2369000 | |
| Shareholding ratio | InterimInstant_No1MajorShareholdersMember | 0.4442 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |